Hepatitis
Eiger halts hepatitis drug development after liver toxicity, seeks funding for other programs
Anika Sharma
Eiger BioPharmaceuticals has made the decision to discontinue the pursuit of a home for peginterferon lambda, a drug that was ...
Gilead’s $8 Million Grant Funding for US Viral Hepatitis Relink Program
SG Tylor
Source – Gilead FGilead Sciences, on July 20, has introduced the Gilead Relink program, a new grant initiative in the ...
Eiger Implements Workforce Reduction as FDA Raises Standards for Hepatitis Drug
SG Tylor
Source – Eiger BioPharmaceuticals On June 29, 2023 Eiger BioPharmaceuticals announced a reduction in staffing by 25% and a strategic ...
